Vanguard New York Tax-Free Funds has released its latest financial report, showcasing a robust total asset figure exceeding $6 billion. This report, filed on October 29, 2026, is significant for both the company and the broader investment landscape.
As an investment entity, Vanguard New York Tax-Free Funds focuses on providing tax-free investment options primarily through municipal bonds. The firm operates under the auspices of the Investment Company Act of 1940, with a strong commitment to serving New York residents.
Background
The Vanguard New York Tax-Free Funds, identified by the Central Index Key (CIK) number 0000788599, is incorporated in Delaware. The firm is primarily engaged in investment activities, specifically targeting tax-free municipal bonds. The latest filing indicates a fiscal year-end of November 30, and the firm has a long history of serving investors looking for tax-efficient investment strategies.
What the Filing Says
The recent filing indicates that the total assets of the fund are approximately $6,036,495,578, with total liabilities amounting to $41,618,205. This results in net assets of about $5,994,877,373. The report also notes that there are no outstanding debts or obligations to banks or affiliates, which reflects a strong financial position.
Impact
This filing may have implications for investors and competitors in the municipal bond market. With significant assets under management, Vanguard New York Tax-Free Funds is well-positioned to attract more investors seeking tax-free income. Other investment firms in the municipal bond sector may need to reevaluate their offerings to remain competitive.
What's Next
The filing does not specify any upcoming actions or changes for Vanguard New York Tax-Free Funds. However, the firm is expected to continue monitoring market conditions and investor needs as it manages its portfolio of tax-exempt securities.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






